Phase 3 randomized trial of chemotherapy with or without oblimersen in older AML patients: CALGB 10201 (Alliance)

Overview of attention for article published in Blood Advances, July 2021

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (83rd percentile)
Good Attention Score compared to outputs of the same age and source (70th percentile)

Mentioned by

news: 1 news outlet

twitter: 2 X users

Readers on

mendeley: 50 Mendeley

So far, Altmetric has seen 1 news story.

Chemotherapy With Antisense Oligonucleotide Oblimersen Improves Disease Free Survival in Older Patients With AML

Cancer Therapy Advisor, 27 Sep 2021

Although adding the ASO did not improve complete remission rates, it appeared to improve disease-free survival in patients with…

This page shows the most recent news stories that mention this research output. Click here to find out how to access more activity.